drugset / Trial / NCT00348725

Acceptability of a Fixed Combination of Fenofibrate and Metformin

NCT00348725

Phase 3 Completed 69 enrolled Solvay Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.

Timeline

Start
2005-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule
Subject Metformin Small molecule

Indications